JP2017520582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520582A5 JP2017520582A5 JP2016575898A JP2016575898A JP2017520582A5 JP 2017520582 A5 JP2017520582 A5 JP 2017520582A5 JP 2016575898 A JP2016575898 A JP 2016575898A JP 2016575898 A JP2016575898 A JP 2016575898A JP 2017520582 A5 JP2017520582 A5 JP 2017520582A5
- Authority
- JP
- Japan
- Prior art keywords
- msc
- composition
- composition according
- subject
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 38
- 210000002536 stromal cell Anatomy 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- -1 CD49A Proteins 0.000 claims description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 210000000577 adipose tissue Anatomy 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 102100024484 Codanin-1 Human genes 0.000 claims description 3
- 101000980888 Homo sapiens Codanin-1 Proteins 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 102000007469 Actins Human genes 0.000 claims description 2
- 108010085238 Actins Proteins 0.000 claims description 2
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 2
- 102100037904 CD9 antigen Human genes 0.000 claims description 2
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 102100036912 Desmin Human genes 0.000 claims description 2
- 108010044052 Desmin Proteins 0.000 claims description 2
- 102100037241 Endoglin Human genes 0.000 claims description 2
- 102000001690 Factor VIII Human genes 0.000 claims description 2
- 108010054218 Factor VIII Proteins 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 2
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 claims description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 2
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100022337 Integrin alpha-V Human genes 0.000 claims description 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 2
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 102000011782 Keratins Human genes 0.000 claims description 2
- 108010076876 Keratins Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 2
- 102000003729 Neprilysin Human genes 0.000 claims description 2
- 108090000028 Neprilysin Proteins 0.000 claims description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 210000005045 desmin Anatomy 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960000301 factor viii Drugs 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007919 intrasynovial administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 2
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14175096 | 2014-06-30 | ||
| EP14175096.8 | 2014-06-30 | ||
| PCT/IB2015/054922 WO2016001845A1 (en) | 2014-06-30 | 2015-06-30 | Mesenchymal stromal cells for treating rheumatoid arthritis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017520582A JP2017520582A (ja) | 2017-07-27 |
| JP2017520582A5 true JP2017520582A5 (enExample) | 2018-08-09 |
| JP6722598B2 JP6722598B2 (ja) | 2020-07-15 |
Family
ID=51033024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575898A Active JP6722598B2 (ja) | 2014-06-30 | 2015-06-30 | 関節リウマチ治療のための間葉系間質細胞 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20170136065A1 (enExample) |
| EP (1) | EP3160480B1 (enExample) |
| JP (1) | JP6722598B2 (enExample) |
| WO (1) | WO2016001845A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109496236A (zh) * | 2016-06-06 | 2019-03-19 | 普拉里斯坦有限公司 | 改变的粘附基质细胞及其产生和使用方法 |
| WO2018062876A2 (ko) * | 2016-09-27 | 2018-04-05 | 가톨릭대학교 산학협력단 | 통증이 경감되는 골관절염 치료용 키트 |
| RU2659204C1 (ru) * | 2017-02-03 | 2018-06-28 | Федеральное государственное автономное образовательное учреждение высшего образования "Балтийский федеральный университет имени Иммануила Канта" (БФУ им. И. Канта) | Биотрансплантат для лечения дисплазии суставов и способ его получения |
| WO2021226455A1 (en) * | 2020-05-07 | 2021-11-11 | Primegen Biotech, Llc | Methods and compositions for reducing joint inflammation using mesenchymal stem cells |
| EP4623302A1 (en) | 2022-11-23 | 2025-10-01 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Biomarkers predictive of immunomodulatory mesenchymal stromal cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ258570A (en) | 1992-12-02 | 1996-06-25 | Shell Int Research | Azoxycyanobenzene derivatives and plant fungicidal compositions |
| US5578475A (en) | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| JP4335310B2 (ja) | 1995-06-07 | 2009-09-30 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用 |
| US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| US5705308A (en) | 1996-09-30 | 1998-01-06 | Eastman Kodak Company | Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element |
| US6777231B1 (en) | 1999-03-10 | 2004-08-17 | The Regents Of The University Of California | Adipose-derived stem cells and lattices |
| PT1926813T (pt) | 2005-09-23 | 2016-09-06 | Consejo Superior Investigacion | Populações de células que têm atividade imunorreguladora, método para isolamento e usos |
| WO2011047345A2 (en) * | 2009-10-15 | 2011-04-21 | Tai June Yoo | Methods of treating diseases of conditions using mesenchymal stem cells |
| KR20140016933A (ko) * | 2011-03-11 | 2014-02-10 | 타이제닉스, 에스.에이.유. | 면역조절 활성을 갖는 세포군, 분리방법 및 용도들 |
| US20160120910A1 (en) * | 2013-06-25 | 2016-05-05 | Tigenix S.A.U. | Cell populations having immunoregulatory activity, methods for the preparation and uses thereof |
-
2015
- 2015-06-30 EP EP15742101.7A patent/EP3160480B1/en active Active
- 2015-06-30 US US15/323,371 patent/US20170136065A1/en not_active Abandoned
- 2015-06-30 WO PCT/IB2015/054922 patent/WO2016001845A1/en not_active Ceased
- 2015-06-30 JP JP2016575898A patent/JP6722598B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017520583A5 (enExample) | ||
| Dabrowska et al. | Immunomodulatory and regenerative effects of mesenchymal stem cells and extracellular vesicles: therapeutic outlook for inflammatory and degenerative diseases | |
| Mei et al. | Advances and clinical challenges of mesenchymal stem cell therapy | |
| Khan et al. | A comparison of phenotypic and functional properties of mesenchymal stromal cells and multipotent adult progenitor cells | |
| JP2017520582A5 (enExample) | ||
| Malgieri et al. | Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art | |
| JP2014000094A5 (ja) | 臍帯由来細胞を用いた局部的または散在的脳外傷の改善 | |
| Kim et al. | Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice | |
| Shi et al. | How mesenchymal stem cells interact with tissue immune responses | |
| AU2014232728B2 (en) | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same | |
| JP2014509319A5 (enExample) | ||
| RU2010153362A (ru) | Способы лечения воспалительных заболеваний ободочной кишки | |
| JP2016523285A5 (enExample) | ||
| Chen et al. | Application of adipose-derived stem cells in heart disease | |
| RU2016151738A (ru) | Мезенхимальные стромальные клетки для лечения синдрома системной воспалительной реакции | |
| JP2021119789A5 (enExample) | ||
| JP2019508455A5 (enExample) | ||
| Gao et al. | The immunosuppressive properties of non-cultured dermal-derived mesenchymal stromal cells and the control of graft-versus-host disease | |
| Sharma et al. | Wharton’s jelly mesenchymal stem cells: Future regenerative medicine for clinical applications in mitigation of radiation injury | |
| Kotenko et al. | Cell technologies in the treatment of radiation burns: experience Burnasyan Federal Medical Biophysical Centre | |
| Kwiecień et al. | Umbilical cord matrix (Wharton jelly) mesenchymal stem cells in Next-generation myocardial repair and regeneration: mechanisms and pre-clinical evidence | |
| Nasef et al. | Human bone marrow-derived mesenchymal stem cells | |
| Najima et al. | Mesenchymal stem cells: the first approved stem cell drug in Japan | |
| EP3053589B1 (en) | Il-17 production inhibitory composition | |
| Baird | Mesenchymal stem cells: how can we realize their therapeutic potential in cancer therapy? |